Drug · DIN 02239665
ALERTEC
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since July 23, 2026; first marketed March 24, 1999.
- Drug Identification Number (DIN)
- 02239665
- Company (DIN owner)
- Neuraxpharm Pharmaceuticals, S.L.Sant Joan Despi, Barcelona, Spain
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Modafinil N06BA07
- Class
- Human
- Record last updated
- August 4, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| MODAFINIL | 100 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 23, 2026: NOC 37989New Drug Submission (NDS) · Administrative: Change in product ownership
- November 19, 2014: NOC 16320New Drug Submission (NDS) · Transfer of drug identification number
- March 21, 2013: NOC 14236New Drug Submission (NDS) · Manufacturer name change
- January 3, 2012: NOC 12905New Drug Submission (NDS) · Manufactrer Name Change
- October 16, 2007: NOC 9097New Drug Submission (NDS) · Manufacturer name change
- November 6, 2003: NOC 1804New Drug Submission (NDS) · Manufacturer name change
- February 26, 1999: NOC 1933New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “alertec”. A notice may cover another product or only some lots: read it to see what it covers.
- ALERTEC (modafinil) and the Risk of Congenital AnomaliesJune 20, 2019 · Drugs · Product safety
- New warnings regarding ALERTEC (modafinil) and serious rash, allergic reactions, and mental problems - For Health ProfessionalsDecember 21, 2007 · Drugs
- Archived - New warnings regarding ALERTEC (modafinil) and serious rash, allergic reactions, and mental problems - For the PublicDecember 21, 2007 · Drugs